source
- TriGemX Bio to go public via SPAC to advance migraine drug candidateTriGemX Bio, formerly known as Kallyope, said it will become a public company by merging with a special purpose acquisition company. The transaction is aimed at raising capital and accelerating the…
- Immunology Society Split Over California’s $8.4 B Proposition 38 Funding MeasureInternal emails obtained by STAT reveal a sharp split within the American Association of Immunologists over California’s Proposition 38, a ballot measure that would direct $8.4 billion of taxpayer…